Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions?

Olivier, Berend; Chan, Johnny S.W.; Pattij, Tommy; Jong, Trynke R. de; Oosting, Ronald S.; Veening, Jan G.; Waldinger, Marcel D.

doi:10.1038/sj.ijir.3901330

Cited by 82 publications

(59 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the third to fourth test individual rats have a very stable and long-lasting level of sexual performance. The number of ejaculations per 30 min is a very reliable and predictive measure of the sexual performance of male rats and we hypothesized that male rats display sexual endophenotypes [26]. Over the last decade we tested (trained) more than 2000 male rats (of the Wistar outbred strain) in this way and we established that such rats might be distributed according to their sexual endophenotype [27,28] in slow (sluggish), average (normal), and fast ejaculators.…”

Section: The Actual Animal Modelmentioning

confidence: 99%

“…Animals with 2-3 ejaculations per test are regarded as "average" or normal ejaculators and constitute the bulk of all rats (60-70%). We hypothesized that male rats notoriously low in sexual performance might model delayed or retarded (an) ejaculation in human males, and those with four or more ejaculations per test reflecting premature ejaculation in men [26].…”

Section: The Actual Animal Modelmentioning

confidence: 99%

See 1 more Smart Citation

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Olivier¹,

Franco²,

Waldinger³

et al. 2017

Sexual Dysfunction

View full text Add to dashboard Cite

Major depression is frequently associated with sexual dysfunctions. Most antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), induce additional sexual side effects and, although effective antidepressants, deteriorate sexual symptoms, which are the main reason that patients stop antidepressant treatment. Many strategies have been used to circumvent the additional sexual side effects, but results are rather disappointing. Recently, new antidepressants have been introduced, vilazodone and vortioxetine, which seem to lack sexual side effects in the early registration trials. Much research with large numbers of depressed patients and adequate methodological tools still has to confirm in daily use the absence of sexual side effects of new antidepressants. Animal models that in an early phase of drug development may predict putative sexual side effects of new antidepressants are extremely useful and could speed up development of new antidepressants. A rat model of sexual behavior is described that has a very high predictive validity for sexual side effects in man. Several characteristics of present antidepressants with regard to sexual dysfunctions are also present in the rat model and establish its validity. The animal model can also be used in the search for new psychotropics without sexual side effects or for drugs with sexual stimulating activity.

show abstract

Section: The Actual Animal Modelmentioning

confidence: 99%

Section: The Actual Animal Modelmentioning

confidence: 99%

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Olivier¹,

Franco²,

Waldinger³

et al. 2017

Sexual Dysfunction

View full text Add to dashboard Cite

show abstract

“…93 In other words, the restriction on the development of animal models of PE is one of the primary factors limiting the development of PE therapy. Olivier et al 94 and Pattij et al 95,96 reported an animal model of PE that could be used to study delayed ejaculation. In this model, a large number of male Wistar rats were observed over 4-6 weeks using sexual behavioural tests.…”

Section: Animal Modelmentioning

confidence: 99%

Current therapeutic strategies for premature ejaculation and future perspectives

Xin¹,

Zhu²,

Yuan³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

Premature ejaculation (PE) is a common sexual disorder in men that is mediated by disturbances in the peripheral and central nervous systems. Although all pharmaceutical treatments for PE are currently used 'off-label', some novel oral agents and some newer methods of drug administration now provide important relief to PE patients. However, the aetiology of this condition has still not been unified, primarily because of the lack of a standard animal model for basic research and the absence of a widely accepted definition and assessment tool for evidence-based clinical studies in patients with PE. In this review, we focus on the current therapeutic strategies and future treatment perspectives for PE. Ejaculation is a tightly coordinated activity with different ejaculatory organs and a spinal reflex initiated by genital and/or brain stimulation through the peripheral sensory receptors and regions, afferent pathways, the central nervous system ejaculatory centre of the brain (namely, sensory and motor areas located in the para-ventricular nucleus of the hypothalamus and the medial preoptic area). The spinal ejaculatory centre, located at the T 12 -L 1-2 spinal cord level (paragigantocellular), and its efferent pathway modulate the function of the ejaculatory organs. Ejaculation is also mediated by a complex interaction of central serotonergic and dopaminergic neurons with the secondary involvement of cholinergic, adrenergic, oxytocinergic and GABAergic neurons.Ejaculation consists of two main phases, the emission phase and the expulsion phase. The emissions include seminal fluid and secretions of the prostate and bulbourethral glands. In this phase, the contraction of accessory ejaculatory organs induces the accumulation of semen in the posterior urethra. Expansion of the posterior urethra creates a feeling of emission and sensory information that is transmitted to the spine via dorsal nerve sensory pathway and along the spinal cord up to the brain ejaculatory centre during the sexual arousal phase. The expulsion phase consists of the highly regular rhythmic contraction of striated muscles and the relaxation of smooth muscles in the ejaculatory ducts. The ejaculated semen can be divided into a number of components by serial biochemical analysis. 1 These include secretions from the seminal vesicles, prostate and bulbourethral (Cowper's) glands and spermatozoa.

show abstract

“…Both human and animal studies showed that serotonin plays an important role in sexual and particularly ejaculatory activity Waldinger, 2005;de Jong et al, 2006;Olivier et al, 2006;Chan et al, 2011). In some cases, a biologic variation in the IELT in men may be because of different regulation of the serotonergic receptor subtypes and/or to other genetic factors.…”

Section: Serotonin (5-ht)mentioning

confidence: 99%

The characterization, current medications, and promising therapeutics targets for premature ejaculation

Gür

Sikka

2015

Andrology

View full text Add to dashboard Cite

SUMMARYPremature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated with negative personal and interpersonal psychological outcomes. The pharmacologic treatment of PE includes the use of antidepressants, local anesthetic agents, and phosphodiesterase type 5 inhibitors. While numerous treatments can control PE, only antidepressants and topical anesthetic creams and sprays have recently been shown to be more effective. This review focuses on the physiology and pharmacology of ejaculation, the pathophysiology of PE and the most effective pharmacological treatment of PE. Pharmacotherapy of PE with off-label shortacting selective serotonin reuptake inhibitors (SSRIs) is common, effective, and safe. Dapoxetine, a SSRI with a short half-life, has been recently evaluated for the treatment of PE by several countries and results are promising. In clinical practice, follow-up side effects are an important part of the management strategy for PE. The understanding of etiology, pathophysiology, and treatment modalities of PE would be beneficial to clinician in helping patients with this disappointing sexual problem.

show abstract

Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions?

Cited by 82 publications

References 76 publications

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Current therapeutic strategies for premature ejaculation and future perspectives

The characterization, current medications, and promising therapeutics targets for premature ejaculation

Contact Info

Product

Resources

About